Immunocompromised individuals 6 months of age and older: Individuals 65 years of age and older who have received one dose of a bivalent COVID-19 vaccine: A dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 4 months after the dose of the bivalent COVID-19 vaccine.Individuals who have received one or more doses of a monovalent COVID-19 vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 2 months after any monovalent COVID-19 vaccine.Unvaccinated individuals: A single dose of Moderna COVID-19 Vaccine, Bivalent.Individuals who have received two doses of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 2 months after the last dose of Moderna COVID-19 Vaccine.Individuals who have received one dose of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered 1 month after the dose of Moderna COVID-19 Vaccine.The second dose is administered 1 month after the first. Unvaccinated individuals: Two doses of Moderna COVID-19 Vaccine, Bivalent are administered.Individuals 6 months through 5 years of age: Moderna COVID-19 Vaccine, Bivalent is now authorized for use as follows: The monovalent Moderna COVID-19 Vaccine is no longer authorized for use in the United States. This action includes authorizing the current bivalent vaccine (Original and Omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older. On April 18, 2023, the Food and Drug Administration amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine, Bivalent to simplify the vaccination schedule for most individuals. Fact Sheets Fact Sheet Translations Información sobre las vacunas para el COVID-19

My blood approves series in order